Transition Therapeutics Inc. (TTHI) announced the results of a 5-week proof of concept clinical study of TT-401 Tuesday morning, in type 2 diabetic and obese non-diabetic subjects. TT-401 demonstrated significant improvements in glycemic control and reductions in body weight.
Transition Therapeutics gapped up and spiked higher at the open Tuesday, before settling into a range. The stock ended the session with a gain of 0.85 at $3.10 on the highest volume of the year. Transition Therapeutics set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.